An Overview of Multiple Drug Hypersensitivity Syndrome
Journal of Pharmacoepidemiology and Risk Management · 2022
DOI: 10.56142/2022.14.1.47 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacoepidemiology and Risk Management, 2022. Verfasst von Kyoung-Hee Sohn. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The multiple drug hypersensitivity syndrome (MDHS) is a novel condition characterized by a delayed hypersensitivity reaction to two structurally different drugs.It is important to be able to distinguish between MDHS and multiple drug intolerance and/or flare-up reactions.MDHS should thus be confirmed using delayed intradermal tests, patch tests or in vitro tests.Recent studies have reported that the initial reactions manifest most commonly as a drug reaction with eosinophilia and systemic symptoms (DRESS); fixed combination antibiotics such as sulfamethoxazole/trimethoprim or piperacillin/tazobactam are frequently involved in MDHS.The occurrence of MDHS depends on the status of previous T cell activations, and its immune response is similar to that seen in graft versus host disease and viral infections.The first drug hypersensitivity response lowers the T cell proliferation threshold for the drug and causes a rapid appearance of hypersensitivity symptoms to the second drug.Accurate diagnosis of MDHS is needed for its proper management.(JPERM 2022;14:47-50) Key Words: Multiple drug hypersensitivity; Drug reaction with eosinophilia and systemic symptoms (DRESS); Drug hypersensitivity 서 론 바야흐로 약물알레르기 진단의 딜레마 시대이다.환자 안전 패러다임
Zitieren
APA
Sohn, K. (2022). An Overview of Multiple Drug Hypersensitivity Syndrome. Journal of Pharmacoepidemiology and Risk Management. https://doi.org/10.56142/2022.14.1.47
Vancouver
Sohn K. An Overview of Multiple Drug Hypersensitivity Syndrome. Journal of Pharmacoepidemiology and Risk Management. 2022. doi:10.56142/2022.14.1.47
BibTeX
@article{Sohn2022,
author = {Sohn, Kyoung-Hee},
title = {An Overview of Multiple Drug Hypersensitivity Syndrome},
journal = {Journal of Pharmacoepidemiology and Risk Management},
year = {2022},
doi = {10.56142/2022.14.1.47}
}
EUVIMED